Talazoparib Dosage

Medically reviewed by Drugs.com. Last updated on Oct 17, 2023.

Applies to the following strengths: 0.25 mg; 0.1 mg; 1 mg; 0.35 mg; 0.5 mg; 0.75 mg

Usual Adult Dose for:

Breast Cancer

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Dose Adjustments
Precautions
Dialysis
Other Comments

Usual Adult Dose for Breast Cancer

1 mg orally once a day until disease progression or unacceptable toxicity

Comments:

Select patients based on the presence of germline BRCA mutations as determined by an FDA-approved test.

Use: For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer

Renal Dose Adjustments

Mild renal impairment: No adjustment recommended
Moderate renal impairment (CrCl 30 to 59 mL/min): 0.75 mg orally once a day
Severe renal impairment (CrCl 15 to 29 mL/min): 0.5 mg orally once a day

Liver Dose Adjustments

No adjustment recommended

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:

Recommended starting dose: 1 mg orally once daily
First dose reduction: 0.75 mg orally once a day
Second dose reduction: 0.5 mg orally once a day
Third dose reduction: 0.25 mg orally once a day

DOSE MODIFICATIONS:

Hemoglobin less than 8 g/dL: Withhold therapy until levels resolve to 9 g/dL or greater; resume therapy at a reduced dose.
Platelet count less than 50,000/microliters: Withhold therapy until levels resolve to 75,000 microliters or greater; resume therapy at a reduced dose.
Neutrophil count less than 1000/microliters: Withhold therapy until levels resolve to 1500 microliters or greater; resume therapy at a reduced dose.
Nonhematologic Grade 3 or 4: Withhold therapy until levels resolve to Grade 1 or less; Consider resuming therapy at a reduced dose or discontinue therapy.

DOSE MODIFICATIONS FOR USE WITH P-GLYCOPROTEIN (P-GP) INHIBITORS:

Reduce the dose to 0.75 mg once daily when coadministered with certain P-gp inhibitors.
When the P-gp inhibitor is discontinued, increase the dose (after 3 to 5 half-lives of the P-gp inhibitor) to the dose used prior to the initiation of the P-gp inhibitor.

Precautions

CONTRAINDICATIONS:

None

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

This drug may be taken with or without food.
The capsules should be swallowed whole and not opened or dissolved.
If the patient vomits or misses a dose, an additional dose should not be taken; take the next prescribed dose at the usual time.

Storage requirements:

Store at 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).

Monitoring:

Monitor complete blood counts monthly.

Patient advice:

Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
Patients should contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions.
Females should inform their healthcare provider if they are pregnant or become pregnant.
Inform female patients of the risk to a fetus and potential loss of the pregnancy.